Minerva Neurosciences, is a drug development company addressing the unmet need of Schizophrenia, with a focus on the negative symptoms of the disease. The company will be entering a pivotal phase 3 clinical trial in the second half of 2017 with 500 patients from the US and Europe. A bit of history into their phase 2b clinical trial produced significant results from this press release Phase IIb study of MIN-101. The company solved three underlying issues that prevented them from being investment suitable.
1. Raising capital with a 5M share offering at $7.75, announced yesterday, bringing total cash to around 118M.
2. Ran a Bridging Study with a BFB-520 metabolite improved MIN-101, and have filed for patent that could exceed 2035 expiration for the GR version.
3. FDA approved their design of the phase 3 pivotal clinical trial that should initiate the second half of 2017.
Quick Facts
Shares: around 41 million
Cash: around 118 million
MIN-101 MR patent: 2035
MIN-101 GR patent: 2035+
There is not an FDA approved drug specifically for negative symptoms of Schizophrenia. Minerva is now in the lead as far as clinical trials initiated with the start of this phase 3 scheduled for the second half of 2017. Thank you for reading.
1. Raising capital with a 5M share offering at $7.75, announced yesterday, bringing total cash to around 118M.
2. Ran a Bridging Study with a BFB-520 metabolite improved MIN-101, and have filed for patent that could exceed 2035 expiration for the GR version.
3. FDA approved their design of the phase 3 pivotal clinical trial that should initiate the second half of 2017.
Quick Facts
Shares: around 41 million
Cash: around 118 million
MIN-101 MR patent: 2035
MIN-101 GR patent: 2035+
There is not an FDA approved drug specifically for negative symptoms of Schizophrenia. Minerva is now in the lead as far as clinical trials initiated with the start of this phase 3 scheduled for the second half of 2017. Thank you for reading.
No comments:
Post a Comment